Suma Krishnan, President, R&D at Krystal Biotech, Inc. (KRYS), sold 87,726 shares at $171.40 ($15.4M) on 2024-06-11, disclosed to the SEC on 2024-06-11.
Scheduled sale ($15.4M) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $171.40 | 900 | $154K | 1.0% |
| 2 | $171.49 | 1,100 | $189K | 1.2% |
| 3 | $172.21 | 1,882 | $324K | 2.1% |
| 4 | $172.21 | 1,882 | $324K | 2.1% |
| 5 | $172.24 | 2,099 | $362K | 2.3% |
| 6 | $172.24 | 2,099 |
| $362K |
| 2.3% |
| 7 | $173.41 | 1,206 | $209K | 1.4% |
| 8 | $173.41 | 1,206 | $209K | 1.4% |
| 9 | $173.49 | 1,318 | $229K | 1.5% |
| 10 | $173.49 | 1,318 | $229K | 1.5% |
| 11 | $174.50 | 1,724 | $301K | 1.9% |
| 12 | $174.83 | 4,000 | $699K | 4.5% |
| 13 | $175.33 | 4,975 | $872K | 5.7% |
| 14 | $175.33 | 4,975 | $872K | 5.7% |
| 15 | $175.76 | 4,550 | $800K | 5.2% |
| 16 | $176.38 | 5,867 | $1.0M | 6.7% |
| 17 | $176.38 | 5,867 | $1.0M | 6.7% |
| 18 | $176.68 | 5,705 | $1.0M | 6.5% |
| 19 | $176.68 | 5,705 | $1.0M | 6.5% |
| 20 | $177.38 | 6,358 | $1.1M | 7.3% |
| 21 | $177.38 | 6,358 | $1.1M | 7.3% |
| 22 | $177.68 | 5,447 | $968K | 6.3% |
| 23 | $177.68 | 5,447 | $968K | 6.3% |
| 24 | $178.14 | 1,871 | $333K | 2.2% |
| 25 | $178.14 | 1,871 | $333K | 2.2% |
| 26 | $178.36 | 998 | $178K | 1.2% |
| 27 | $178.36 | 998 | $178K | 1.2% |
| Total | $175.93 avg | 87,726 | $15.4M | 100% |
| Filing → |
| KRYS | SELL | 2026-03-06 | $13.2M | — | Filing → |
| KRYS | SELL | 2025-12-05 | $20.9M | — | Filing → |
| KRYS | SELL | 2025-07-16 | $10.1M | — | Filing → |